Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Core Viewpoint - Biogen Inc. has seen a slight increase in share price of approximately 1.1% since the last earnings report, outperforming the S&P 500, but there are concerns about potential downward trends leading up to the next earnings release [1]. Group 1: Earnings Estimates - Estimates for Biogen have trended downward over the past month, with a consensus estimate shift of -9.02% [2]. - The overall direction and magnitude of estimate revisions indicate a downward shift, leading to a Zacks Rank of 3 (Hold) for Biogen, suggesting an expectation of in-line returns in the coming months [4]. Group 2: VGM Scores - Biogen currently holds a subpar Growth Score of D, a Momentum Score of C, and an impressive Value Score of A, placing it in the top 20% for value investment strategy [3]. - The aggregate VGM Score for Biogen is C, which is relevant for investors not focused on a single strategy [3]. Group 3: Industry Performance - Biogen is part of the Zacks Medical - Biomedical and Genetics industry, where Gilead Sciences has gained 7% over the past month [5]. - Gilead reported revenues of $7.57 billion for the last quarter, reflecting a year-over-year increase of +6.4$1.90 compared to $1.72 a year ago [5]. - Gilead is expected to post earnings of$1.73 per share for the current quarter, indicating a year-over-year change of +231.1%, and has a Zacks Rank of 2 (Buy) with a VGM Score of B [6].